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Abstract
Introduction: In Greece, fusidic acid and clindamycin are commonly used for the empiric therapy of suspected
staphylococcal infections.
Methods: The medical records of children examined at the outpatient clinics or admitted to the pediatric wards of
the University General Hospital of Larissa, Central Greece, with community-associated staphylococcal infections
from January 2003 to December 2009 were reviewed.
Results: Of 309 children (0-14 years old), 21 (6.8%) had invasive infections and 288 (93.2%) skin and soft tissue
infections (SSTIs). Thirty-five patients were ≤30 days of age. The proportion of staphylococcal infections caused by
a community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) isolate increased from 51.5% (69 of
134) in 2003-2006 to 63.4% (111 of 175) in 2007-2009 (P = 0.037). Among the CA-MRSA isolates, 88.9% were
resistant to fusidic acid, 77.6% to tetracycline, and 21.1% to clindamycin. Clindamycin resistance increased from 0%
(2003) to 31.2% (2009) among the CA-MRSA isolates (P = 0.011). Over the 7-year period, an increase in multidrug-
resistant CA-MRSA isolates was observed (P = 0.004). One hundred and thirty-one (93.6%) of the 140 tested MRSA
isolates were Panton-Valentine leukocidin-positive. Multilocus sequence typing of 72 CA-MRSA isolates revealed
that they belonged to ST80 (n = 61), ST30 (n = 6), ST377 (n = 3), ST22 (n = 1), and ST152 (n = 1). Resistance to
fusidic acid was observed in ST80 (58/61), ST30 (1/6), and ST22 (1/1) isolates.
Conclusion: In areas with high rate of infections caused by multidrug-resistant CA-MRSA isolates, predominantly
belonging to the European ST80 clone, fusidic acid and clindamycin should be used cautiously as empiric therapy
in patients with suspected severe staphylococcal infections.
Background
Since the late 1990’s, an increasing number of reports
from different parts of the world have described the
occurrence of infections caused by community-
associated methicillin-resistant Staphylococcus aureus
(CA-MRSA) [1-5]. The presence of genes encoding for
toxins such as Panton-Valentine leukocidin (PVL)
appears to contribute to increased virulence of CA-
MRSA isolates [6,7]. The vast-majority of CA-MRSA
infections is skin and soft-tissue infections (SSTIs); how-
ever, certain cases can progress to invasive tissue infec-
tions and bacteremia.
Clindamycin has been used successfully in the treat-
ment of both invasive and non-invasive CA-MRSA
infections in children [8,9]. So, many clinicians use clin-
damycin as an empiric antimicrobial therapy for sus-
pected staphylococcal infections. In addition, there is an
increase in the use of antibiotics such as vancomycin,
which may add further to the problem of antibiotic
resistance in the hospital and the community [10].
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the staphylococcal cassette chromosome (SCC) mec type
IV and the accessory gene regulator (agr)a l l e l e3 ,
belonging to a clone C, identical to European CA-
MRSA ST80, was initially identified in Patras in 1998
[11]. Following that observation, an increased incidence
of CA-MRSA infections has been recognized among
Greek children and adults [12].
In Greece, clindamycin, vancomycin, rifampin, and
fusidic acid are the most commonly used non-b-lactam
antistaphylococcal agents. In addition, quinolones are
also being used, but almost exclusively in adults. Fusidic
acid has been a common choice for empiric antistaphy-
lococcal therapy, both parenterally and orally adminis-
tered. In infections requiring parenteral therapy, it is
recommended that fusidic acid should be administered
in combination with another antistaphylococcal antibio-
tic [13]. Before the spread of CA-MRSA, a b-lactam was
most often used in this combination.
The University General Hospital of Larissa (UGHL)
serves as the academic, tertiary care referral center for
the broader area of Central Greece. The aim of the pre-
sent study was to evaluate a) the clinical manifestations
of community-associated S. aureus infections in children
who were examined at the outpatient clinics or hospita-
lized in the pediatric wards of the UGHL during a
7-year period and b) the possible changes in the pheno-
type and the genotype of the recovered MRSA isolates
over the same time-period.
Methods
Patients
The medical records of children 0-14 years of age exam-
ined at the outpatient clinics or admitted to the
pediatric wards of the UGHL, Central Greece, with
community-associated staphylococcal infections from
January 2003 to December 2009 were reviewed. In the
present study, the research conformed to the Helsinki
Declaration and to local legislation. The research proto-
col was approved by the Ethics Committee of the
UGHL.
Community-associated infections were defined as
those in which the S. aureus strain was isolated in a
clinical specimen obtained within 48 hours from admis-
sion without hospitalization or surgery, indwelling
catheter, prosthetic devices or positive MRSA culture
within the preceding 1 year [2]. A standard preformed
questionnaire was filled out for each patient including
demographic data, type of infection-diagnosis, site of
positive culture, surgical intervention, antibiotic treat-
ment and outcome.
A case of invasive infection was defined by 1 or more
of the following conditions: bacteremia, pneumonia,
mastoiditis, lymphadenitis, septic arthritis, osteomyelitis,
pyomyositis or another illness in which S. aureus was
isolated from normally sterile body fluids. A diagnosis of
staphylococcal pneumonia was made if the patient had
radiographic abnormalities compatible with pneumonia
a n dt h eb l o o do rp l e u r a lf l u i dc u l t u r ew a sp o s i t i v ef o r
S. aureus. Infections involving the skin or soft tissue
structures were regarded as SSTIs.
Patients were excluded if a diagnosis of S. aureus
infection was made on the basis of positive S. aureus
cultures obtained from the nose, axilla, or perineum or
if they had a positive culture but no signs of disease.
Patients with an orbital or otogenic infection were
excluded if the S. aureus isolates were recovered from
the swabs of the eye or ear drainage only [10].
S. aureus identification and antimicrobial susceptibility
testing
The clinical microbiology laboratory of the UGHL iso-
lated and identified S. aureus strains by standard proce-
dures [12]. Antimicrobial susceptibility testing was
performed using the disk diffusion method according to
Clinical and Laboratory Standards Institute (CLSI)
recommendations and definitions [14,15] for oxacillin,
fusidic acid, erythromycin, clindamycin, gentamicin,
ciprofloxacin, tetracycline, trimethoprim-sulfamethoxa-
zole, rifampin, vancomycin, linezolid, and mupirocin
(BBL, Becton Dickinson, Le Pont de Claix, France). MIC
to oxacillin was determined by use of an E-test (AB Bio-
disk, Solna, Sweden) according to the manufacturer’s
recommendations and was interpreted according to
CLSI guidelines [15]. In addition, MIC to mupirocin of
the mupirocin-resistant isolates was determined by use
of an E-test. For fusidic acid, where CLSI does not pro-
vide disk susceptibility breakpoints, the required dia-
meters for susceptibility and resistance were ≥22 mm
and <22 mm, respectively (10-μg disc) according to the
European Committee on Antimicrobial Susceptibility
Testing (EUCAST) clinical breakpoints [16].
For isolates that tested resistant to erythromycin but
susceptible to clindamycin, a D-test was performed to
detect inducible resistance to clindamycin. Among
MRSA, multidrug resistance was defined as resistance
to three or more non-b-lactam antimicrobial agents
(ciprofloxacin, clindamycin, erythromycin, gentamicin,
tetracycline, rifampin, fusidic acid, trimethoprim-
sulfamethoxazole, vancomycin, and linezolid).
Detection of genes encoding S. aureus virulence factors
One hundred and forty of the 180 CA-MRSA isolates
and 55 of the 129 community-associated methicillin-
susceptible S. aureus (CA-MSSA) isolates of different
antibiotic resistance patterns were randomly selected for
the PVL testing. DNA was extracted from these 195
S. aureus isolates and polymerase chain reaction was
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duction (luk-S-PV and luk-F-PV). Primers and polymer-
ase chain reaction conditions have been reported
previously [12]. S. aureus ATCC 49775 was used as a
positive control for the PVL genes.
Multilocus sequence typing (MLST)
Seventy-two MRSA isolates of different antibiotic resis-
tance patterns were randomly selected and further ana-
lyzed by MLST as previously described [17].
Statistical analysis
To assess the annual hospital admission rates, groups of
patients, and collections of isolates during the 7-year
study period, categorical parameters were compared
using the c
2 for trend. In assessing two groups, continu-
ous parameters were compared using Mann-Whitney
U test and categorical parameters were compared using
Fisher’se x a c tt e s t .P < 0.05 was considered statistically
significant. The statistical analysis was carried out with
the software product SPSS version 13.0.
Results
During the study period, 309 children with community-
associated S. aureus infections were identified from the
database by a computer-assisted laboratory-based sur-
veillance and medical record review; 180 (58.3%) had an
infection due to an MRSA isolate. One hundred fifty-
one (48.9%) of the 309 children were inpatients.
Characteristics of patients with MRSA and MSSA
infections
Patients from whom an MRSA isolate was recovered
were significantly younger than those with MSSA
(Table 1). Among the hospitalized children with an
invasive staphylococcal infection, the mean ± SD age
was 7.4 ± 5.4 years for MSSA and 2.8 ± 3.8 years for
MRSA infection (P = 0.035). Among the hospitalized
children with SSTIs, the mean ± SD age was 3.6 ± 4.0
years for MSSA and 2.5 ± 3.0 years for MRSA infection
(P = 0.072).
The monthly distribution of community-associated S.
aureus isolates during the 7-year study period demon-
strated an increasing number of isolates during the sum-
mer and autumn (Figure 1).
Infections caused by CA-MRSA and CA-MSSA strains
Of the 309 S. aureus infections, 35 (11.3%) occurred
during the first month of life and 10 (3.2%) during the
2nd and 3rd month (Table 2). These 45 young infants
with S. aureus infection were previously healthy, were
born at ≥37 weeks’ gestation, and presented with a S.
aureus infection after nursery discharge. MRSA was
recovered from 23 (65.7%) of the 35 neonates with no
history of admission to NICU or other hospitalizations
since birth and no surgeries. In very young infants,
MRSA infections were significantly more common than
the MSSA ones (P = 0.0004).
Two hundred sixty-four (85.4%) of the 309 children
with S. aureus infection were older than 90 days of life.
The sites and types of invasive and non-invasive infec-
tions after the 3rd month of life appear in Table 3. Over
the 7 years of the study, all the children with invasive
S. aureus infections survived.
Of the total 180 CA-MRSA isolates, 168 (93.3%) were
recovered from children with SSTIs and 12 (6.7%) from
children with invasive infections. Of the 129 CA-MSSA
isolates, 120 (93.0%) were associated with SSTIs and 9
(7.0%) with invasive infections.
Table 1 Characteristics of 309 patients with community-
associated Staphylococcus aureus infections
Characteristic MSSA MRSA P
n = 129 n = 180
Age, years
All patients
median (range) 4.5 (0.02 - 14) 1.7 (0.02 - 14)
mean ± SD 4.8 ± 4.0 2.7 ± 3.0 < 0.001
Inpatients 52 99
median (range) 2.4 (0.02 - 14) 1.2 (0.02 - 14)
mean ± SD 4.3 ± 4.5 2.5 ± 3.1 0.005
Outpatients 77 81
median (range) 5.0 (0.04 - 13) 2.0 (0.04 - 11)
mean ± SD 5.2 ± 3.5 3.1 ± 2.9 < 0.001
Male gender 70 (54.3)
a 88 (48.9) 0.359
Season
June - November 97 (75.2) 125 (69.4) 0.306
Hospitalization 52 (40.3) 99 (55.0) 0.011
anumber in parentheses is percent, unless otherwise indicated.
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Figure 1 Monthly distribution of community-associated
Staphylococcus aureus infections in children at the University
General Hospital of Larissa from 1 January 2003 through 31
December 2009.
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those with CA-MRSA isolates and 35.8% (43 of 120) of
those with CA-MSSA isolates were admitted to the hospi-
tal (P = 0.008). MRSA isolates accounted for a significantly
higher proportion of SSTIs, such as furunculosis and
abscesses, compared to MSSA isolates (P <0 . 0 0 5 ) .
The annual distribution of cases and admission rates
(number of cases per 1000 hospital admissions) during
the 7-year study period are shown in Figure 2. The
annual admission rates of community-associated infec-
tions caused by MRSA increased yearly (x
2 for trend,
P = 0.0004). This change reflected mainly the increase
in the rate of admissions for MRSA SSTIs (P = 0.0004).
The yearly increase of the annual admission rates of
community-associated infections caused by MSSA iso-
lates was of a lesser degree compared to those due to
MRSA (x
2 for trend, P = 0.053).
Antibiotic susceptibility
Over the 7 years of the study, a significant increase in
the resistance to methicillin and clindamycin was noted
among the 309 S. aureus isolates (Figure 3). The propor-
tion of staphylococcal infections caused by a CA-MRSA
isolate increased from 51.5% (69 of 134) in 2003-2006
to 63.4% (111 of 175) in 2007-2009 (P = 0.037). Among
the CA-MRSA isolates, 21.1% exhibited resistance to
clindamycin, which specifically increased from 0%
(2003) to 31.2% (2009) (x
2 for trend, P = 0.011). In addi-
tion, a trend of rise in the rate of clindamycin resistance
Table 2 Community-associated Staphylococcus aureus
infections during the first 90 days of life
Feature Age
1-30 days 31-60
days
61-90 days
n=3 5 n=5 n=5
Age, days
Median (range) 14 (7 - 30) 46
(32 - 60)
82 (63 - 90)
Mean ± SD 15.6 ± 5.3 46.6 ±
10.0
77.6 ± 12.5
Male gender 17 (48.6)
a 3 (60.0) 2 (40.0)
Infection MSSA MRSA MRSA MSSA MRSA
n=
12
n=2 3 n=5 n=2 n=3
Pneumonia with
empyema
0 2 (8.7) 1 (20.0) 1
(50.0)
1
(33.3)
Septicemia 1 (8.3) 0 0 0 0
Pustulosis 5
(41.7)
11
(47.8)
1 (20.0) 0 2
(66.7)
Impetigo 2
(16.7)
0 1 (20.0) 0 0
Furuncle 1 (8.3) 2 (8.7) 1 (20.0) 1
(50.0)
0
Abscess 1 (8.3) 1 (4.3) 0 0 0
Cellulitis 0 1 (4.3) 0 0 0
Mastitis ± abscess 1 (8.3) 6 (26.1) 0 0 0
Omphalitis 1 (8.3) 0 0 0 0
Paronychia 0 0 1 (20.0) 0 0
anumber in parentheses is percent, unless otherwise indicated.
Table 3 Clinical features of patients >3 months old with
community-associated Staphylococcus aureus infections
Type of infection MSSA MRSA P
n=
115
n=
149
Invasive
Arthritis 3 (2.6)
a 1 (0.7) 0.321
Osteomyelitis 2 (1.7) 0 0.189
Pyomyositis/osteomyelitis with
bacteremia
1 (0.9) 1 (0.7) 0.999
Bursitis with bacteremia 1 (0.9) 0 0.436
Pneumonia 0 2 (1.3) 0.506
Periorbital cellulitis with bacteremia 0 1 (0.7) 0.999
Soft tissue infection with bacteremia 0 2 (1.3) 0.506
Cervical lymphadenitis 0 1 (0.7) 0.999
SSTIs
Impetigo 68
(59.1)
27
(18.1)
<0.001
Folliculitis 1 (0.9) 3 (2) 0.635
Unspecified pustular lesions 11 (9.6) 8 (5.4) 0.232
Ecthyma 2 (1.7) 0 0.189
Furuncle 9 (7.8) 55
(36.9)
<0.001
Abscess 4 (3.5) 22
(14.8)
0.003
Cellulitis 7 (6.1) 19
(12.7)
0.095
Paronychia 2 (1.7) 4 (2.7) 0.700
Mastitis 0 1 (0.7) 0.999
Infected wound 4 (3.5) 2 (1.3) 0.409
anumber in parentheses is percent
S. aureus invasive diseases
MRSA invasive diseases admission rates MRSA SSTIs admission rates
S. aureus SSTIs
MSSA invasive diseases admission rates MSSA SSTIsa d missionr ates
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Figure 2 Number of cases and admission rates (number of
cases per 1000 hospital admissions) of community-associated
Staphylococcus aureus infections among hospitalized pediatric
patients.
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percentage of clindamycin resistance in MRSA isolates
from 2007 to 2009 has been 23.8-31.2% and that of
MSSA isolates 15.4-38.1%. The highest rate of clindamy-
cin resistance among the MRSA and MSSA isolates was
observed in 2009.
Resistance to fusidic acid was observed in 88.9% (160
of 180) of MRSA isolates and 22.5% (29 of 129) of
MSSA (P < 0.001). Tetracycline resistance was noted in
7 7 . 6 %( 1 3 9o f1 7 9 )o fM R S Ai s o l a t e sa n d2 0 . 1 %( 2 6o f
129) of MSSA (P < 0.001). Resistance to gentamicin was
noted in 3.9% (7 of 180) of MRSA isolates and none of
the 129 MSSA ones (P = 0.044). Resistance to mupiro-
cin was observed in 2 (0.98%) of the 205 tested S.
aureus isolates and both of them were MSSA. In addi-
tion, there was only one MSSA isolate resistant to tri-
methoprim-sulfamethoxazole and another one to
ciprofloxacin. All S. aureus isolates were susceptible to
rifampin, vancomycin, and linezolid.
During the 7-year study period, a significant increase
in multidrug-resistant (MDR) CA-MRSA isolates was
observed (x
2 for trend, P =0 . 0 0 4 ) .A m o n gt h eM R S A
isolates, MDR increased from 0% (2003) to 31.2% (2009)
(x
2 for trend, P = 0.011). Overall, 38 (21.1%) of 180
MRSA isolates were MDR compared with 9 (7.0%) of
129 MSSA isolates (P = 0.001). The rate of MDR MRSA
isolates increased mainly during the second part of the
present study, ie between 2007 and 2009, and compared
to the rate during the years 2003-2006 reached a statisti-
cally significant level in the group of children with SSTIs
(Table 4). An MDR CA-MRSA isolate was recovered
from 20 (13.2%) of 151 inpatients and from 18 (11.4%)
of 158 outpatients (P = 0.729).
Molecular analysis of S. aureus isolates
PVL-positive were 131/140 (93.6%) of the MRSA and 7/
55 (12.7%) of MSSA isolates. Among the tested MRSA
isolates, all 11 isolates associated with invasive infections
were PVL-positive as well as 120/129 (93%) of the iso-
lates that caused SSTIs. In contrast, only 2 (25%) of the
8 tested MSSA isolates associated with invasive infec-
tions were PVL-positive as well as 5 (10.6%) of the 47
MSSA isolates from SSTIs.
MLST analysis of the 72 tested MRSA isolates showed
that they belonged to ST80 (n = 61), ST30 (n = 6),
ST377 (n = 3), ST22 (n = 1), and ST152 (n = 1). Resis-
tance to fusidic acid was observed in ST80 (58/61),
ST30 (1/6), and ST22 (1/1) isolates. Among the ST80
MRSA isolates, 6 resistance patterns were observed; the
two most common patterns exhibited resistance to oxa-
cillin, fusidic acid, and tetracycline (n = 37) and oxacil-
lin, fusidic acid, tetracycline, erythromycin, and
clindamycin (n = 11). Of the 61 tested ST80 MRSA iso-
lates, 16 (26.2%) were resistant to clindamycin expres-
sing the inducible type of resistance. PVL-positive were
mainly isolates belonging to ST80 and ST377. Of the 56
ST80 MRSA isolates that were tested for the PVL pro-
duction, 54 (96.4%) were PVL-positive. In addition, all
three ST377 isolates carried PVL genes. Only 2 MSSA
isolates were analyzed by MLST; one belonged to ST152
and the other to ST489.
Discussion
In Central Greece over the 7-year study period, MRSA
strains have widely spread in the community and since
2005 account for >50% of all S. aureus isolates recov-
ered from children with community-associated infec-
tions. These MRSA isolates are often MDR, exhibiting
resistance to fusidic acid, tetracycline, erythromycin, and
clindamycin. It appears to be a sustained phenomenon
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Figure 3 Percentage of Staphylococcus aureus isolates with
resistance to methicillin, fusidic acid, and clindamycin during
the 7-year study period.
Table 4 Characteristics of Staphylococcus aureus isolates
according to the study period and the type of infection
Type of infection, isolate 2003-2006 2007-2009 P
n = 134 n = 175
Invasive 8 13
MRSA 4 (50.0)
a 8 (61.5) 0.673
MDR-MRSA 0 3 (23.1) 0.261
PVL-positive/MRSA tested 4/4 (100) 7/7 (100) 0.999
SSTIs 126 162
MRSA 65 (51.6) 103 (63.6) 0.054
MDR-MRSA 9 (7.1) 26 (16.0) 0.028
PVL-positive/MRSA tested 50/57 (87.7) 70/72 (97.2) 0.430
anumber in parentheses is percent
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sive use of antibiotics may have contributed to this high
frequency of MRSA isolates.
In our area, 85% of the tested MRSA isolates belonged
to the European ST80. This finding suggests that the
increase in MRSA infections is associated with the
predominance and spread of a single clone in the com-
munity, which is the European ST80 [18,19]. Recent
reports document the identification of the European
ST80 clone also in Algeria [5], Tunisia [20], and
Southern Israel [21].
It is not known why ST80 is so capable of rapidly
spreading in a community or why it causes infections
seemingly more readily than other S. aureus clones. The
molecular analysis revealed that 93.6% of the MRSA iso-
lates from Central Greece were PVL-positive. The sug-
gested role of PVL in enhancing the organism’s ability to
spread rapidly or to increase severity of invasive infec-
tions is under investigation [7,22]. In addition, other fac-
tors are currently also investigated. A recent study
described a class of secreted staphylococcal peptides that
have a remarkable ability to recruit, activate and subse-
quently lyse human neutrophils, thus eliminating the
main cellular defense against S. aureus infection [23].
As a consequence of the wide spread of such isolates
in the community, the number of cases of SSTIs and
invasive infections due to MRSA has increased across all
ages. Of the 309 infections, 11.3% occurred during the
first month of life. This is in accordance with the litera-
ture from areas with high rate of CA-MRSA [24,25].
Among the studied children with SSTIs, the propor-
tion of cases admitted to the hospital was significantly
higher in the group of patients with an MRSA infection
than in those infected by an MSSA isolate. The differ-
ence in hospitalization frequencies is consistent with the
CA-MRSA infections being more severe than the MSSA
infections. The identification and antibiotic susceptibil-
ities of the isolates were not known at the time of
admission.
Fusidic acid is considered to be a very active agent for
S. aureus and is available in intravenous, oral and/or
topical (skin and ophthalmic) preparations. It has been a
good choice for parenteral therapy, preferably as combi-
nation treatment, in moderate/severe suspected staphy-
lococcal infections. However, in the present 7-year
study, fusidic acid-resistant isolates, MRSA or MSSA,
accounted for invasive infections and SSTIs. Resistance
to this antibiotic has also been detected in CA-MSSA
[26-28] as well as CA-MRSA strains [18,29-32] from
other European countries. Both clonal [26] and non-clo-
nal [28] dissemination of fusidic acid-resistant S. aureus
have been well documented to occur in the community.
In contrast to CA-MRSA isolates from other conti-
nents, those belonging to the European ST80 clone have
been reported to frequently express reduced susceptibil-
ity to fusidic acid and commonly carry the plasmid-
located far-1 (also known as fusB) gene encoding fusidic
acid resistance [18,32]. It is notable that in some pre-
vious reports from Europe these isolates have been
reported as intermediate to fusidic acid [18]. This is
related to the fact that due to the nonexistence of CLSI
breakpoints for fusidic acid the authors had applied the
previous breakpoints of the French Society for Micro-
biology [33]. According to these breakpoints, MICs of 4
to 16 μg/ml were considered indicative of an isolate
intermediate to fusidic acid, whereas the breakpoint for
resistance was ≥32 μg/ml. In 2010, the EUCAST break-
points have been accepted in Europe and MICs of ≥2
μg/ml are considered representing resistance to fusidic
acid [16]. Recently, Jones et al. have evaluated the activ-
ity of fusidic acid against S. aureus isolates using broth
microdilution, disk diffusion, and Etest methods and
proposed ≤1 μg/ml (disk zone ≥22 mm) as breakpoints
for susceptibility and ≥4 μg/ml (disk zone ≤19 mm) for
resistance [34].
In Greece, despite the high prevalence of fusidic acid-
resistant S. aureus isolates in the community, the use of
oral and/or topical (skin and ophthalmic) preparations
of fusidic acid continues to be extensive (authors’
unpublished data). Parenterally administered fusidic acid
is used at a lower scale, but yet attention should be paid
to this, as it usually concerns patients with severe infec-
tions. The prolonged use of fusidic acid as topical
monotherapy for chronic skin conditions appears to
have resulted in the emergence of resistance among
S. aureus isolates in some countries [35,36], making this
agent less active both for topical and systemic therapy
[35]. In areas with high rate of fusidic acid resistance,
topical and oral or systemic fusidic acid monotherapy
should be restricted, in order to prevent the further
spread of fusidic acid-resistant S. aureus isolates [35].
Topical use of a valuable systemically active agent is
best to be avoided [36]. High frequency of fusidic acid
resistance may persist despite such restrictions and may
represent the development of a fusidic acid-resistant
S. aureus reservoir in the community.
Since the time that the increase of CA-MRSA infec-
tions was well appreciated, clindamycin, an antibiotic
that is considered to be active against a high percentage
of CA-MRSA and MSSA isolates, has been extensively
used empirically, particularly in pediatric infections
[8,37]. In areas with low rate of clindamycin resistance,
clindamycin is the recommended empirical antistaphylo-
coccal therapy for hospitalized pediatric patients with
clinical entities likely caused by CA-MRSA, such as
cutaneous abscesses or pneumonia with empyema. In
parallel to the antistaphylococcal activity, clindamycin
possesses the ability to suppress production of PVL by
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[38]. In the present study, PVL was produced by most
of the MRSA isolates.
According to our recent data, the rate of clindamycin
resistance in MRSA isolates from 2007 to 2009 has been
23.8-31.2% and that of MSSA isolates 15.4-38.1%. With
the increased rates of clindamycin resistance among CA-
MRSA and CA-MSSA isolates in our area, clindamycin is
not useful for empiric monotherapy treatment for sus-
pected S. aureus invasive infections and severe SSTIs.
Thus, one should reconsider the empirical treatment
regimen, which, in our area, until recently consisted pri-
marily of clindamycin or vancomycin. Empirical clinda-
mycin treatment for suspected staphylococcal infections
is not recommended in areas where the proportion of
CA-MRSA isolates exceeds 10% to 15% [37]. Among sta-
phylococcal infections due to isolates exhibiting inducible
clindamycin resistance [39,40], the risk of treatment fail-
ure during clindamycin therapy is increased when there
is a high bacterial inoculum [39].
In Greece, tetracycline resistance is common among
the CA-MRSA isolates. This is a significant difference
between the European ST80 clone and the USA300 [3].
Actually in the United States, oral tetracyclines, such as
minocycline or doxycycline, are used as an alternative
treatment for suspected S. aureus SSTIs in children
8 years of age and older [41]. Tetracyclines are particu-
larly prescribed by the dermatologists. In Central
Greece, trimethoprim-sulfamethoxazole and ciprofloxa-
cin resistance appeared to be rare, whilst vancomycin,
rifampin, and linezolid susceptibility was universal, rein-
forcing the utility of these compounds for the time
being at least.
The increasing rate of CA-MRSA infections has impor-
tant implications for patient management and for the
selection of appropriate antimicrobial therapy. If possible,
single treatment which is active against both MSSA and
MRSA should be considered as an empirical therapy in
patients with staphylococcal infections. However, caution
should be paid in monotherapy, as well as in combination
therapy, using antibiotics recently recognized as having
reduced activity against S. aureus. Currently in Central
Greece, vancomycin, linezolid, or daptomycin, as mono-
therapy or in combination with rifampin or gentamicin,
appear to be choices for empiric therapy of severe or dif-
ficult to treat possible staphylococcal infections. Vanco-
mycin is inferior to nafcillin for the treatment of invasive
MSSA infections including bacteremia and endocarditis.
Some experts have proposed nafcillin or another penicil-
linase-resistant penicillin in combination with an agent
active against MRSA isolates, such as vancomycin, for
critically ill patients [37]. If a penicillinase-resistant peni-
cillin is used as an empiric combination therapy, atten-
tion should be paid to the selection of the second
antibiotic. Trimethoprim-sulfamethoxazole is another
treatment choice, particularly in SSTIs.
Mild/moderate SSTIs can be empirically treated with
clindamycin or trimethoprim-sulfamethoxazole [41,42],
either alone or in combination with rifampin. However,
optimal management for pediatric CA-MRSA SSTIs has
yet to be determined because of limited clinical studies
and efficacy data. Drainage of the abscesses is the key to
treatment and is helpful in isolating the causative patho-
gen. A number of studies have shown primarily good
outcomes in patients whose abscess is drained regardless
of the antibiotics administered [43,44].
There were several possible limitations to our study.
This was a retrospective study with its inherent limita-
tions in data availability. We did not have detailed infor-
mation on maternal infection history or that of other
family members, especially for the very young infants.
Additionally, although we tried to classify the infections
as accurately as possible, a small number of patients with
SSTIs which was mainly described in the charts as pyo-
dermatitis, was classified as “unspecified pustular
lesions”. However, this does not influence the statistical
analysis for impetigo. Infections classified as impetigo
were clearly described with this diagnosis in the medical
records. Finally, the molelular analysis of the isolates was
based on MLST typing of representative isolates. Pulse-
field gel electrophoresis could have provided additional
information on the clonal relationship of the isolates.
Because antimicrobial resistance continues to evolve, it
is important to continue monitoring S. aureus infections
in our area. This provides valuable data on resistance
trends and contributes to more effective treatment recom-
mendations for regional and national use. Physicians car-
ing for children throughout Europe and the world are
likely to face the same problem with CA-MRSA that we
have described in this report, as the ST80 or other CA-
MRSA clones are introduced into their communities.
Conclusions
We have described the epidemiology, clinical manifesta-
tions, and antibiotic resistance of the causative agents in
pediatric community-associated S. aureus infections in
Central Greece. We found that MRSA is increasing as a
cause of skin and soft tissue infections, as well as of the
invasive ones, among all ages. In our area, the sustained
phenomenon of the wide spread in the community of
MRSA strains is predominantly due to isolates belonging
to the European ST80. Among the MRSA isolates, 88.9%
were resistant to fusidic acid and 77.6% to tetracycline.
The percentage of clindamycin resistance in MRSA iso-
lates from 2007 to 2009 has been 23.8-31.2% and that of
MSSA isolates 15.4-38.1%. In areas with high rate of
infections caused by multidrug-resistant CA-MRSA iso-
lates, predominantly belonging to the European ST80
Katopodis et al. BMC Infectious Diseases 2010, 10:351
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tiously as empiric therapy in patients with suspected
severe staphylococcal infections.
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